Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00595426 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery
A Phase 2 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 685
- Enrollment target
NCT00595426: Completed Phase 2 study, sponsored by Astellas Pharma.
NCT00595426 is a Phase 2 study that has completed, run by Astellas Pharma. The registered enrollment target is 685 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (415% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00595426, a Phase 2 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 685 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of twice daily dosing and once daily dosing of YM150 in subjects undergoing primary elective knee replacement surgery
Interventions
- DRUG Warfarin
- DRUG YM150
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 685 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
What the finished NCT00595426 record still lists
NCT00595426 is an interventional study that assigns participants to a tested intervention. The registered 685 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (415% higher).
The record links to 0 conditions, and to 2 interventions - of which Warfarin is the first listed.
NCT00595426 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00595426 about?
NCT00595426 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery". To evaluate the safety and efficacy of twice daily dosing and once daily dosing of YM150 in subjects undergoing primary elective knee replacement surgery
What is the current status of trial NCT00595426?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 685 participants. The study started on 2008-05. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00595426?
The interventions under investigation include: Warfarin (DRUG), YM150 (DRUG).
Who is sponsoring clinical trial NCT00595426?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00595426's enrollment target sits among peer trials
685 48th of 2000 higher than 1,953 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05099770 · 685 participants · Phase 3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
- NCT05880199 · 685 participants
BSGM to Evaluate Patients With GI Symptoms
- NCT04333537 · 686 participants · Phase 2
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- NCT06459180 · 686 participants · Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia